Document Detail

Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
MedLine Citation:
PMID:  16153395     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Individual variability in the therapeutic response to an antihypertensive drug could have a genetic basis. We investigated whether the alpha1A-adrenergic receptor (alpha1A-AR) Arg347Cys polymorphism is associated with the blood pressure (BP) therapeutic response to irbesartan and whether the association could be altered by the plasma irbesartan level. METHODS: A total of 696 hypertensive subjects were treated with a daily oral dose of 150 mg irbesartan. Baseline BP was measured before the first dose. On the 28th day, after 27 consecutive days of treatment and an overnight fast, BPs and blood samples were obtained before the morning dose (0 hours) and 6 hours after the morning dose was taken. Plasma irbesartan concentrations were measured by use of HPLC-fluorescence. RESULTS: BP therapeutic response was defined as baseline BP minus BP on the 28th day of irbesartan treatment. Relative to noncarriers, alpha1A-AR Cys347 allelic carriers had a significantly greater diastolic blood pressure (DBP) response at 0 hours (mean +/- SD, 7.5 +/- 8.4 mm Hg versus 5.5 +/- 8.4 mm Hg; P = .016) and at 6 hours (16.2 +/- 9.1 mm Hg versus 14.2 +/- 8.9 mm Hg, P = .025). Although the pattern was similar to the DBP response, alpha(1A)-AR Cys347 allelic carriers had only a moderately increased systolic blood pressure (SBP) response at the 2 time points. When subjects were stratified into subgroups with high or low plasma irbesartan concentrations (with the median value used as the cutoff point), Cys347 allelic carriers in the high-concentration group, relative to noncarriers, had a more pronounced DBP response at 0 hours (adjusted beta [+/- SE], 3.0 +/- 1.0 mm Hg; P = .004) and at 6 hours (adjusted beta, 3.0 +/- 1.2 mm Hg; P = .014), and the same was true for the SBP response at 0 hours (adjusted beta, 5.6 +/- 2.1 mm Hg; P = .006) and at 6 hours (adjusted beta, 4.7 +/- 2.0 mm Hg; P = .021). In contrast, in the low-concentration group, there was no significant association between DBP or SBP responses and Arg347Cys genotypes at 0 hours and 6 hours. CONCLUSION: Our data suggest that the alpha1A-AR Arg347Cys polymorphism is associated with BP response (particularly DBP) to short-term irbesartan treatment. Our data also showed evidence of an interaction between the alpha1A-AR Arg347Cys polymorphism and the plasma level of irbesartan in relation to BP therapeutic response. The association of the Arg347Cys polymorphism with the BP therapeutic response was more pronounced in those patients with higher plasma concentrations of irbesartan.
Shanqun Jiang; Guangyun Mao; Shanchun Zhang; Xiumei Hong; Genfu Tang; Zhiping Li; Xue Liu; Yan Zhang; Binyan Wang; Xiping Xu; Xiaobin Wang
Related Documents :
18685605 - The effects of sour tea (hibiscus sabdariffa) on hypertension in patients with type ii ...
19353775 - Treatment of obstructive sleep apnoea in samoa progressively reduces daytime blood pres...
17097955 - Efficacy and safety of valsartan, an angiotensin ii receptor antagonist, in hypertensio...
14763035 - A selective angiotensin receptor antagonist, valsartan, produced regression of left ven...
17315605 - The genetic basis for altered blood vessel function in disease: large artery stiffening.
20504125 - Plasma apelin and adma levels in patients with essential hypertension.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  78     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-12     Completed Date:  2005-09-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-48     Citation Subset:  AIM; IM    
School of Life Sciences, University of Science and Technology of China, Anhui, Hefei, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Substitution
Antihypertensive Agents / blood,  pharmacokinetics*,  therapeutic use*
Biphenyl Compounds / blood,  pharmacokinetics*,  therapeutic use*
Blood Pressure / drug effects*,  genetics*
Chromatography, High Pressure Liquid
Circadian Rhythm
Linear Models
Middle Aged
Polymorphism, Genetic / physiology
Receptors, Adrenergic, alpha-1 / genetics*
Spectrometry, Fluorescence
Tetrazoles / blood,  pharmacokinetics*,  therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Receptors, Adrenergic, alpha-1; 0/Tetrazoles; 0/adrenergic receptor alpha(1a); 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo.
Next Document:  The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.